Clinical trial · Observational
Electroporation for Cancer Treatment Real World Registry
NCT04929912CI-TRIAL-00085227PIONEERrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of Treatment-Emergent Adverse Events (CTCAE)
- timeFrame
- 5 years
- description
- Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. The investigation will be put on hold if unacceptable safety issues are outstanding. Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE)
Secondary outcomes (1)
- measure
- Response Evaluation Criteria in Solid Tumours (RECIST)
- timeFrame
- 3 months, 12 months, 3 years, 5 years
- description
- A response evaluation will be conducted at standard of care follow up
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Any patient who has been treated using Calcium Electroporation * Any patient who has been treated using Electrochemotherapy * Patients must be mentally capable of understanding the information given * Patients must give written informed consent. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.